Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 101 to 110 of 426 total matches.
Drugs for Chronic Insomnia
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
of falls.
The Medical Letter ® Vol. 65 (1667) January 9, 2023
2
Benzodiazepine receptor agonists ...
Cognitive behavioral therapy for insomnia (CBT-I) is
recommended for initial treatment of chronic insomnia.
CBT-I includes stimulus control, sleep education
and hygiene, sleep restriction, relaxation training, and
cognitive therapy. When CBT-I alone is not effective,
pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6 doi:10.58347/tml.2023.1667a | Show Introduction Hide Introduction
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
The Medical Letter ® Vol. 65 (1674) April 17, 2023
58
Table 1. Empiric Treatment of Some Outpatient ...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62 doi:10.58347/tml.2023.1674a | Show Introduction Hide Introduction
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
creatinine
clearance, have been reported with long-term use of
The Medical Letter ® Vol. 66 (1699) April 1 ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
by methotrexate.
The Medical Letter ® Vol. 63 (1637) November 15, 2021
Table 1. Some Conventional DMARDs ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
completion of therapy.
The Medical Letter ® Vol. 64 (1647) April 4, 2022
50
recommended. PPIs decrease ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
Letter ® Vol. 65 (1684) September 4, 2023
138
Table 1. Drugs for Maintenance Treatment of Opioid Use ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction
Drugs for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
involving the face and intertriginous areas. The Medical Letter ® Vol. 66 (1712) September 30, 2024
154 ...
Mild to moderate plaque psoriasis can be treated
with topical drugs and phototherapy. Patients
with moderate to severe disease generally require
systemic therapy. Guidelines for the treatment of
psoriasis with topical therapy, phototherapy, and
systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60 doi:10.58347/tml.2024.1712a | Show Introduction Hide Introduction
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025 (Issue 1734)
to achieve weight loss of
The Medical Letter ® Vol. 67 (1734) August 4, 2025
at least 10% (81.6% vs 60.5 ...
Overweight is generally defined as a body mass
index (BMI) between 25 and 29.9 kg/m2 in adults. A
BMI ≥30 is considered obese (criteria differ slightly in
Asian patients). In patients with an elevated BMI, a
5-10% reduction in weight has been associated with
a reduction in the risk of developing type 2 diabetes,
hypertension, and dyslipidemia. Diet, exercise, and
behavior modification are the traditional methods
for losing weight, but they are often inadequate; the
American College of Cardiology no longer recommends
that all patients try lifestyle modification alone before
adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8 doi:10.58347/tml.2025.1734a | Show Introduction Hide Introduction
Seasonal Influenza Vaccination: 2026-2027
The Medical Letter on Drugs and Therapeutics • Oct 12, 2026 (Issue 1765)
consistent
direction while the federal advisory process remains paused.
The Medical Letter ® Vol. 68 (1765 ...
Annual influenza vaccination is recommended for all persons
≥6 months old without a contraindication. Influenza
vaccines available this season in the US are listed in Table 3.
Med Lett Drugs Ther. 2026 Oct 12;68(1765):161-7 doi:10.58347/tml.2026.1765a | Show Introduction Hide Introduction
In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
/policies/drug-pricing-policy.
The Medical Letter ® Vol. 65 (1668) January 23, 2023 torsemide bumetanide ...
The FDA has approved Furoscix (scPharmaceuticals),
a subcutaneous formulation of the loop diuretic
furosemide administered via a single-use, on-body
infusor, for treatment of congestion due to fluid
overload in adults with New York Heart Association
(NYHA) Class II-III chronic heart failure (HF).
Furosemide (Lasix, and generics) has been available
for years in oral and IV formulations.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):14-5 doi:10.58347/tml.2023.1668d | Show Introduction Hide Introduction
